Rocket Pharmaceuticals (RCKT) Current Leases (2019 - 2026)

Rocket Pharmaceuticals has disclosed Current Leases across 8 years of filings, most recently posting $998000.0 for Q1 2026.

• Current Leases for Q1 2026 came in at $998000.0, down 0.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $998000.0 (down 0.8% YoY), and the FY2025 annual result was $1.0 million, down 45.96% from the prior year.
• Current Leases came in at $998000.0 for Q1 2026 at Rocket Pharmaceuticals, roughly flat from $1.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.9 million in Q3 2025 to a low of $737000.0 in Q2 2022.
• The 5-year median for Current Leases is $1.2 million (2023), against an average of $1.4 million.
• Peak annual rise in Current Leases reached 149.05% in 2022, while the deepest fall reached 54.23% in 2022.
• Rocket Pharmaceuticals' Current Leases stood at $773000.0 in 2022, then surged by 131.69% to $1.8 million in 2023, then advanced by 3.63% to $1.9 million in 2024, then tumbled by 45.96% to $1.0 million in 2025, then retreated by 0.5% to $998000.0 in 2026.
• The last three Current Leases figures came in at $998000.0 (Q1 2026), $1.0 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.